* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Download Update and New Perspectives on HSV Infections, Paulo R. Cunha
Meningococcal disease wikipedia , lookup
Onchocerciasis wikipedia , lookup
Influenza A virus wikipedia , lookup
Cysticercosis wikipedia , lookup
Hepatitis C wikipedia , lookup
Ebola virus disease wikipedia , lookup
African trypanosomiasis wikipedia , lookup
Microbicides for sexually transmitted diseases wikipedia , lookup
Middle East respiratory syndrome wikipedia , lookup
Anthrax vaccine adsorbed wikipedia , lookup
Sexually transmitted infection wikipedia , lookup
West Nile fever wikipedia , lookup
Human cytomegalovirus wikipedia , lookup
Neonatal infection wikipedia , lookup
Whooping cough wikipedia , lookup
Orthohantavirus wikipedia , lookup
Marburg virus disease wikipedia , lookup
Henipavirus wikipedia , lookup
Hepatitis B wikipedia , lookup
Neisseria meningitidis wikipedia , lookup
Herpes simplex wikipedia , lookup
21st World Congress of Dermatology Oct/2007 “Update and new perspectives on HSV infections” Paulo R. Cunha, MD, PhD. Professor of Dermatology Jundiaí Medical School São Paulo, Brazil Introduction Over 70% of the population has been infected by either HSV-1 or HSV-2 Produce: primary, latent and recurrent infections. Clinical manifestation: “benign and malign” Extragenital Herpes: 80-90%: HSV-1 Genital Herpes: (normally sexual transmission) 80-90%: HSV-2 DNA Virus Serological techniques: HSV-1: glycoprotein gC1 HSV-2: glycoprotein gC2 Keratinocyte Cytoplasm Herpes virus Capsid DNA HSV Capsomers Cell membrane Virus new particle Acyclovir Cytoplasmic Membrane Timidina Kinase (TK) Acyclovir Monophosphate Acyclovir Triphosphate Genital Herpes: CDC Treatment Recommendations First clinical genital herpes episode (mg for 7–10 days) Valacyclovir Acyclovir Famcyclovir 1000 bid 400 tid 200 5/day 250 tid* Recurrent genital herpes episodic suppressive (mg days) (mg, daily) 500 bid (3†-5 d) 500 qd‡ 1000 qd (5 d) 1000 qd 400 tid (5 d) 800 bid (5 d) 200 5/day (5 d) 125 bid (5 d) 400 bid 250 bid up to 1 year *Not FDA approved †New FDA-approved dosing ‡May be less effective in patients who have very frequent recurrences (10 episodes/year) Centers for Disease Control and Prevention. MMWR. 2002;51(RR-6)12-17. Issues to be considered in Suppressive Therapy Not necessary to wait 6 outbreaks in 12 months Define impact of genital herpes Gravity and duration of the outbreak New Therapeutic Options 1) Analog of nucleoside Cidofovir (gel 0.3 or 1%) Single-dose confers a significant antiviral effect on lesions of recurrent genital herpes. Antimicrob Agents Chemother 1998 Nov;42(11):2996-9 New Therapeutic Options 2) Immunomodulator Resiquimod (gel 0.05%) Significant reduction in number of recurrences J Infect Dis 2001 Jul 15;184(2):196-200 New Therapeutic Options 3) Fusion Inhibitor Docosanol (Abreva®) (cream 10%) interferes with the process of viral fusion with the host cell. Effective treatment for recurrent HSL. J Am Acad Dermatol 2001 Aug; 45 (2): 222-30) New Therapeutic Options 4) Direct action in DNA polimerase of HSV Foscarnet is the choice in pts with HSV resistant to acyclovir. It is effective in destroying the virus timidina kinase lacking (nephrotoxicity). Rio Dermatológico 2001 July/August/September Foscarnet (cream 2%) is an effective and safe medication in the treatment of HSL. Hautarzt. 2006 Jan;57(1):40-6 New Therapeutic Options 5) Helicase inhbitors (Phase III) Could increase the intervals between the crises and it is more effective then acyclovir Nature Med. 8,392-398, 2002). (Phase III) Treatment of Recurrent Herpes Simplex with L-Lysine Decreases recurrence and severity Long-term: L-Lysine 1 g/day Avoid: Arginine, “Herpetogenic” foods like chocolate, peas, cola drinks, grain cereals, peanuts, gelatin, cashews, beer. Encourage: Lysine, Foods like dairy products, milk, potatoes, brewer’s yeast. New Antiherpes Vaccines by Genetic Engineering An ideal vaccine should induce Cellular and Humoral Immune Response adequate to prevent infection. Vaccines by genetic engineering PCMV T7His6EK BGH f1 SV40 N SV40 ColE1 pA ori ori pA Amp Vaccines with DNA of plasmid that contains the codes of viral glycoproteins (pcDNA3.1/His A,B,C 5.5 kb ) Plasmid insertion Chromosome transformed bacteria Plasmid transference Cellular and Humoral Immune Response Herpes Virus Vaccine: News and Perspectives The most hopeful result was obtained with HSV-2 gD2 and alum/MPL vaccine (Glaxo SmithKline) in clinical studies. -74% effective in preventing genital disease -Only in women who had never been exposed to HSV previously. -Not effective in men Herpes Virus Vaccine: News and Perspectives DISC (Disabled Infectious Single Cycle) virus HSV vaccine contains a virus with deletion of an essential gene (gH gene), so the replication has been limited to a single cycle only. Guinea pigs were protected from a primary infection. Significant protection from recurrent disease was also observed. Herpes Virus Vaccine Studies Prophylactic Vaccines for HSV-2 Genetically engineered HSV to produce a vaccine that is protective without causing human disease is in development. Using a vaccine with live attenuated HSV from which neurovirulence gene (gamma 1 34.5) has been removed, has debilitated HSV in its ability to establish latency and be reactivated. Animals vaccinated are able to elicit protective immune responses Mikrobiyol Bul. 2006 Oct;40(4):413-33 Conclusions HSV Vaccine is still a challenge. Seronegative individuals at high risk for infection represent ideal candidates for vaccine trials. Individuals with frequent recurrences are not significantly responsive to vaccines so far. Promising approaches to engineered HSV vaccines should be possible within the next several years. We are in the right road but we have to keep walking. Sexual education, campaigns of information and the use of preservative continues to be essential. Thank you! [email protected]